Abstract Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of mature T-and NK-cell neoplasms, the incidence of which is higher in Asian countries than in Western countries. Although its etiology is mainly unknown, several risk factors (such as genetic factors, abnormal immunity, environmental factors, and infectious causes) have been proposed. PTCL are classified based on a combination of several parameters, including morphology, site of presentation, viral status, immunophenotype, and specific genetic alterations. Their classification is ongoing, with the emergence of new entities and refinement of existing entities because of the development of diagnostic markers and new genetic alterations. This review presents epidemiologic data for PTCL in Asia, together with recent progress in the pathology of PTCL compared with the WHO 2008 classification.
The incidence and distribution of the T-and NK-cell lymphomas in Asia. a The frequency of T-and NK-cell lymphomas is relatively high in East Asia and Southeast Asia compared to West Asia and South Asia. b The frequency and subtypes of T-or NK-cell lymphoma in China show regional difference ranges from 20.7 to 32.5 % (Fig. 1) . ENKL is the most common subtype of T-or NK-cell lymphoma in Shandong (northern China) and Sichuan (southwestern China), whereas PTCL, NOS, or T-LBL is the most common form in Shanghai (southern China) and Shanxi (northern China) [14, 16] . India shows an intermediate distribution pattern, between West Asian and East Asian countries: the frequency of T-or NK-cell lymphoma is usually higher than in the Western literature, but less than the frequency documented in some Asian countries. The frequency of ENKL (4.5 %) is similar to that reported in other Indian studies [10, 17] .
Node-based T-cell lymphomas
Angioimmunoblastic T-cell lymphoma Angioimmunoblastic T-cell lymphoma (AITCL) is a major subset of PTCLs, accounting for 16, 28.7, and 17.9 % of mature T-cell lymphoma in North America, Europe, and Asia, respectively [2] . In Asia, proportion of AITCL among all T-and NK-cell lymphomas was 9.7 % in Japan, 9.4 % in China, 7.8 % in Korea, 7.2 % in Thailand, 6.9 % in India, and 4.1 % in Taiwan [4, [8] [9] [10] [11] [12] . AITCL is a primarily nodal disease with unique clinical findings. The patients are middle-or old-aged individuals who usually present with systemic lymphadenopathy, hepatosplenomegaly, constitutional symptoms, and skin rashes. The tumor is composed of a polymorphic infiltrate, including neoplastic T cells, plasma cells, immunoblasts, and small B cells with arborizing highendothelial venules, and a dense meshwork of follicular dendritic cells (Fig. 2) . Neoplastic cells express CD3, CD4, CXCR5, CD57, and BCL6, which are markers of normal follicular helper T (TFH) cells, and PD-1, CD10, ICOS-1, and CXCL-13 [18] . Although PD-1 is the most sensitive marker for the detection of TFH cells, the proportion of PD-1-positive T cells among CD3-positive lymphocytes is often much lower, suggesting that many AITCL cases have notoriously low tumor contents. Almost all cases harbor an Epstein-Barr virus (EBV)-infected B-cell population, which reflects a defect in the T-cell immune surveillance that eradicates the virus.
Follicular helper T cells are crucial for the establishment of germinal center reactions and the generation of high-affinity antibodies, memory B cells, and long-lived plasma cells. Overstimulation of TFH cells, linked with a dysregulated humoral immune response, can explain the peculiar clinical findings of AITCL, including B-cell proliferation, marked plasmacytic differentiation, hypergammaglobulinemia, and Coombs-positive hemolytic anemia [19, 20] . Many patients with AITCL show 
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The data of China [12] did not clarify the proportion of T-LBL, but mentioned that most of LBL were T-lineage. 30.2 % of NHL cases were mature T-and NK-cell lymphomas when lymphoblastic lymphomas were excluded NHL non-Hodgkin's lymphoma, PTCL peripheral T-cell lymphoma, NOS not otherwise specified, ENKL extranodal NK/T cell lymphoma, AITCL evidence of immunodeficiency, with a reduction of T cells, an inverted CD4/CD8 ratio, and defective T-cell function in vivo and in vitro [21] . Reports of the development of clonal T-cell proliferation mimicking AITCL in chronic immunosuppressive condition suggest a role of the underlying immune defect in the pathogenesis of AITCL [22, 23] . These patients usually exhibit an aggressive clinical course and show a dismal outcome with the current therapies [24] . In accordance with pathological findings, the gene expression profile of AITCL shows a specific TFH cell signature and a strong microenvironment imprint [25] . Recently, isocitrate dehydrogenase 2 (IDH2) mutation was identified by Sanger sequencing in about 20 % of AITCL cases [26] . The mutations are not specific to malignant lymphoma; rather, they seem to be specific for AITCL, as no other subtypes of malignant lymphoma had this mutation. TET gene mutation is common in mature T-cell lymphoma, as it was observed in 47 % of AITCL and 37 % of PTCL, NOS, especially with a follicular helper T-cell phenotype [27] . TET2 mutation is frequently accompanied by DNMT3 mutation, which is involved in cytosine methylation. Mutation of epigenetic regulators, including TET2, DNMT3, and IDH2, is involved in the epigenetic control of transcription, and the oncogenic cooperation between epigenetic regulators seems to play a role in the pathogenesis of AITCL.
Peripheral T-cell lymphoma, NOS, follicular variant (PTCL-F)
The follicular variant of T-cell lymphoma (PTCL-F) is described as a variant of PTCL, NOS, in the 2008 WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues [28] . The histological appearance of PTCL-F is variable and consists of atypical clear cells that form intrafollicular aggregates (mimicking follicular lymphoma), small nodular aggregates in a background of progressively transformed germinal centers (mimicking nodular lymphocyte-predominant Hodgkin's lymphoma), or an enlarged perifollicular zone (mimicking nodal marginal zone lymphoma) [28] . The overall architecture is often minimally or partially effaced. PTCL-F displays a TFH phenotype and usually expresses more than three TFH-cell markers, including PD-1, CXCL-13, ICOS-1, CD10, CD4, and BCL-6. Phenotypic overlapping with AITCL has raised the question of a possible relationship between the two lymphoma types [29] . PTCL-F was not grouped with AITCL in the 2008 WHO classification because of its presentation in a low-stage, partial organ involvement, lower frequency of polymorphous reactive background, and lack of hyperplastic high-endothelial venules compared with typical AITCL; however, recent accumulating clinical, morphological, and genetic evidence suggest that PTCL-F may not be a distinct entity; rather, it may represent a spectrum of AITCL [30] . Clinically, the coexistence of PTCL-F and AITCL in the same patient has been reported [31] . Some patients who were initially diagnosed with AITCL relapsed with PTCL-F [32] . Morphologically, some cases of PTCL-F can show many morphological features of AITCL, including focal regressed follicles, high-endothelial venule hyperplasia, and focal follicular dendritic cell expansion [30] . Genetically, a novel t(5;9)(q33;q22) mutation that results in the fusion of ITK-SYK was reported in 21 % of PTCL-F cases. The ITK-SYK fusion is not unique to PTCL-F, as it has been reported in a few cases of PTCL, NOS, and AITCL [30, 33, 34] , suggesting that a common genetic alteration is shared among TFH-cell neoplasms.
Anaplastic large-cell lymphomas ALK-positive ALCL ALK-positive ALCL shows a broad morphological spectrum with a variable proportion of hallmark cells and a translocation involving the ALK gene, with expression of the ALK protein and CD30 (Fig. 3 ) [35] . ALK-positive ALCL accounts for 16, 6.4, and 3.2 % of mature T-cell lymphoma in North America, Europe, and Asia, respectively [2] . It affects mostly the lymph nodes, with extranodal involvement observed in 60 % of cases, most commonly in soft tissue and bone [36, 37] . Primary involvement of the skin and brain is rare, as only a few cases have been reported [30, 38, 39] . The majority of primary cutaneous ALK-positive ALCL cases reported recently had a small-cell component. The ALK protein was expressed in the cytoplasm and nucleus, indicating an underlying NPM-ALK fusion in most cases. Primary cutaneous ALCL is regarded as part of the spectrum of primary cutaneous CD30-positive T-cell lymphoproliferative disorders that are negative for the ALK protein. The histopathological and clinical pictures of the skin-restricted ALK-positive ALCL are indistinguishable from those of primary cutaneous ALCL, raising the necessity of performing ALK staining in all cases of ALCL encountered in the skin [38] .
ALK-negative ALCL
ALK-negative ALCL represents 7.8, 9.4, and 2.6 % of mature T-cell lymphomas in North America, Europe, and Asia, respectively [2] . ALK-negative ALCL is defined as a CD30? T-cell neoplasm that is not reproducibly distinguishable based on morphological features from ALKpositive ALCL, but lacks the ALK protein, according to the 2008 WHO classification [40] . In conjunction with strong and abundant CD30 expression in almost all cells, other features that favor this diagnosis are the absence of a B-cell program, as demonstrated by the lack of Pax5 expression (with the exception of cases with PAX5 gene amplification), loss of T-cell markers, expression of EMA, a cytotoxic phenotype, and lack of T-cell receptor (TCR) expression [41, 42] . ALK-negative ALCL presents with lymph-node involvement in 70 % of cases, and extranodal spread is less common compared with ALK-positive ALCL [40] . The patients have an overall survival rate that lies between those of patients with PTCL, NOS and ALKpositive ALCL [36, 41] . Because the distinction between PTCL, NOS, and ALK-negative ALCL is not always clearcut, ALK-negative ALCL was included in the WHO 2008 classification as a provisional entity; however, emerging evidence shows that it is distinct from PTCL, NOS. Gene expression profiling revealed that gene clusters, including TNFRSF8, SNFT, NFATC2, and PERP, distinguish ALKnegative ALCL from PTCL, NOS and AITCL [43] . RT-PCR analysis of TNFRSF8, BATF3, and TMOD1 successfully distinguished ALK-negative ALCL from PTCL, NOS [44] . MicroRNA expression profiling identified molecular signatures that differentiated ALK-negative ALCL from other PTCLs [45] . A balanced translocation that disrupted the DUSP22 phosphatase gene on chromosome 6p25.3 and adjoined the FRA7H fragile site on chromosome 7q32.3 was identified in up to 45 % of ALK-negative ALCL cases [46] . Although the role of such a molecular alteration remains to be determined, the signature specificity for ALK-negative ALCL suggests that this lymphoma represents a unique entity that is discernible from other PTCLs.
Primary breast-implant-related ALK-negative ALCL
Breast-implant-associated ALCL is a rare clinicopathological entity that has been reported in up to 103 cases to date. Most cases had an ALK-negative phenotype, with the exception of a few ALK-positive cases [47, 48] . It arises in association with the fibrous capsule or effusion around the silicone breast implant [47] . Tumor cells are large immunoblast-like cells with conspicuous nucleoli and degrees of nuclear pleomorphism that express CD30 with variable expression of other T-cell markers, including CD3 in 46 %, CD4 in 84 %, TIA-1 in 63 %, granzyme B in 61 %, and CD8 in 15 % of cases, as shown in non-implant-associated ALCL [47] . EBV is negative. An extensive mixed lymphocytic infiltrate adjacent to the fibrous implant capsule suggests the potential role of chronic inflammation and genetic instability in the pathogenesis of breast-implantassociated ALK-negative ALCL [49] . These patients have a good prognosis when the tumor presents solely with effusions around the implant [48] ; in contrast, patients who present with a distinct mass may have advanced stage or possibly systemic disease and have a poorer prognosis [50] .
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Gastrointestinal T-cell lymphomas
In Asian countries, T-lineage mature T-cell lymphomas account for up to 6 % of all gastrointestinal NHL [8] . In the stomach, the frequency of T-cell lymphoma is much lower compared with the intestine and accounts for \5 % of cases [8] . In the intestine, the proportion of T-cell lineage NHLs is 12 % in Korea [8] , 14.7 % in Japan [51] , and 32-40.8 % in China [52, 53] . PTCL, NOS is the most common subtype, followed by enteropathy-associated T-cell lymphoma (EATL) and ENKL [8, 54, 55] .
Enteropathy-associated T-cell lymphoma EATL has two forms, type I and type II, with different clinical and pathological features. Type I is characterized by a polymorphous cytological composition, usually an ab T phenotype, but with cd T cells in some cases, and is associated with celiac disease. Type II shows a monomorphic cytology with usually a cd T-cell phenotype expressing CD8 and CD56, with some cases of ab T cells (Fig. 4) . Usually, celiac disease is not associated [56] . In the study performed by the international PTCL project, EATL constituted 5.4 % of all T-cell lymphomas and was most common in Europe (9.1 %), followed by North America (5.8 %), and Asia (1.9 %). EATL type I was more common (66 %) than type II (34 %), and was especially frequent in Europe (79 %) [57] . In Asia, most EATL was type II, accounting for 100 % of EATL in China, 83 % in Japan, and 87.5 % in Korea [55, [58] [59] [60] . In a recent Asian collaborative study, patients with EATL were mostly adult males (median age 58 years, male:female ratio 2.6:1), presenting with abdominal pain (60 %), intestinal perforation (40 %), and weight loss (28 %). None had a history of celiac disease, and the median survival was only 7 months [61] . EATL is a neoplasm of intraepithelial T lymphocytes (IEL) [56] . Among the subset of IEL, type b IEL is far more prevalent in the mucosal epithelium and expresses ab TCRs or TCRs with a unique coreceptor, CD8aa, or lacks CD8 and CD4. Although the small and large intestines contain both type a and type b IELs, the ratio between type a and type b IELs differs markedly. The small intestine is rich in CD8aa IELs, whereas the large intestine contains very few of these cells [62] . The T-cell subset of EATL exhibited a predominance of cd T cells in a study from China. Fourteen (78 %) cases expressed cd TCRs, and only six (33 %) expressed ab TCRs (with three cases coexpressing both TCRs) [59] . In an Asian collaborative study, TCR expression was silent or not evaluable in 40 % of cases, whereas the remaining cases exhibited predominant expression of TCRab over TCRcd (1.6:1). The immunophenotype was CD8?/CD56? (88 %) cytotoxic T cell and there was frequent aberrant expression of CD20 (24 %). In keeping with the normal ratio of IEL subsets, CD8? cases showed predominant CD8aa homodimer expression (77 %), regardless of TCR lineage [61] .
Indolent T-cell and NK-cell lymphoproliferative diseases
Indolent T-or NK-cell proliferative diseases, which may be mistaken for aggressive T-cell or NK-cell lymphoma, have been described in the GI tract [63, 64] . Lymphomatoid gastropathy or NK-cell enteropathy is a nonprogressive NK-cell proliferative lesion of unknown etiology that often regresses spontaneously, even when left untreated. The histological features of these cases include superficial, but confluent, infiltration of medium or large cells, with a moderate-to-abundant clear cytoplasm and a variable proportion of cells with peculiar eosinophilic granules in the cytoplasm [64] . EBER in situ hybridization is always negative, which is an important differential feature from ENKL. The lineage of infiltrated cells is assumed to be NK cells, because they have a CD2?/-and cytoplasmic CD3?, CD4-, CD7?, CD8-, CD56?, TIA1?, granzyme B? phenotype, and the TCR gene rearrangement is polyclonal [64] . Similar indolent proliferations of T cells were reported involving the oral cavity, esophagus, stomach, small intestine, and colon. The infiltrates were nondestructive and composed of small, mature-appearing lymphoid cells that were clonal, CD8-positive and, less commonly, CD4-positive or CD4/CD8-negative T cells. The clinical course is indolent, and none of the patients showed progression of tumor size or the extent of involvement [65] .
Primary cutaneous T-cell lymphomas
Primary cutaneous lymphomas are defined as cutaneous lymphomas (CTLs) that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. The estimated annual incidence of this condition is 1:100,000 in the USA [66] . The proportion of the T-cell subtype is higher in Korea (81.6-84.3 %) [67, 68] and Japan (80-86.8 %) [69, 70] than it is in the USA (71.3 %) and Europe (77.6 %) [71, 72] . The most common subtypes in Western countries are MF/SS, CD30? lymphoproliferative disorder of the skin (CD30? LPD), and PTCL in Europe, and MF/SS, PTCL, and CD30? LPD in the USA, in decreasing order of frequency [71, 72] . In Asia, the major subtype is MF/SS, followed by CD30? LPD in Korea and Japan [67] [68] [69] [70] . The third most common subtype was PTCL or ATLL in Japan [69, 70] . A recent Korean nationwide study revealed that the most common subtypes in that country are MF/SS, PTCL, CD30? LPD, and ENKL, in decreasing order of frequency (unpublished data). The frequency of PTCL of primary cutaneous T-cell lymphomas (PCTLs) is variable, ranging 9.2-12.3 % in Korea and from 4.3 to 16 % in Japan [67] [68] [69] [70] . PTCL encompasses PTCL, NOS, primary cutaneous cd T-cell lymphoma (cdTCL), primary cutaneous CD8? aggressive epidermotropic cytotoxic T-cell lymphoma (CD8TCL), and primary cutaneous CD4? small/medium T-cell lymphoma (CD4TCL). The incidence of PTCL subtypes (cdTCL, CD8TCL, and CD4TCL) has not been clarified in Asia, because these subtypes were included in the WHO 2008 classification as provisional entities and are difficult to differentiate from other CTLs. In one Korean study, the proportion of PTCL was 12.3 % of all PCTLs and consisted of CD4TCL (50 %), PTCL, NOS (30 %), and cdTCL (20 %) [68] .
Primary cutaneous cd T-cell lymphoma
Primary cutaneous cd T-cell lymphoma (cdTCL) is a neoplasm of activated cd T cells with a cytotoxic phenotype [73] . Patients present with multiple nodules on the trunk and limbs or generalized ulcerated plaques. Its histological findings are variable and include upper dermal infiltration with marked epidermotropism with ulceration of the epidermis, diffuse dermal infiltration, or involvement of the subcutis with a subcutaneous panniculitis-like pattern [74] . Most patients experience an aggressive clinical course with extranodal and nodal dissemination [74, 75] . The identification of primary cutaneous cdTCL was difficult until the TCRc and TCRd antibodies for paraffinsection immunohistochemistry became available commercially. In the two most recent studies, the immunophenotype of cd TCL was CD4-/CD8-in six cases and CD4-/ CD8? in five cases. TCRc or TCRd was detected in all cases, with simultaneous expression of bF1 in one case [74, 75] . All cases express cytotoxic granules that include granzyme B, perforin, and TIA-1. TCRc expression is not exclusive to cdTCL, as it can be found in other CTLs, including lymphomatoid papulosis or mycosis fungoides [74] . The diagnosis should be made on the proper clinical and pathologic context. The genetic and cytogenetic abnormalities of cdTCL have not been investigated well. One study demonstrated the presence of several chromosomal translocations involving breakpoints at chromosomes 9p21, 14q11.2, 14q32.1, or 16q23.1, suggesting the involvement of WWOX, the TCL gene cluster, and BCL11B [76] .
Primary cutaneous CD8? aggressive epidermotropic cytotoxic T-cell lymphoma Primary cutaneous CD8? aggressive epidermotropic cytotoxic T-cell lymphoma (CD8TCL) is an aggressive CTL that is derived from epidermotropic CD8? cytotoxic ab T cells. The immunophenotype of this tumor is always CD4-/ CD8?. Because the CD4-/CD8? phenotype is not exclusive to CD8TCL, other CD8? TCLs, including CD8? mycosis fungoides, lymphomatoid papulosis type D, and indolent CD8? lymphoproliferation of the ear or acral sites, should be differentiated based on pathological and clinical findings [77] [78] [79] . The prognosis of this disease is usually poor, which can be attributed to highly aggressive clinical lesions that usually result in a rapid metastatic spread, a lower response rate to chemotherapy, and a higher incidence of relapse [77] . Conversely, some cases with a favorable outcome have been reported [78, 79] , suggesting that CD8TCL has a heterogeneous clinical behavior. In this regard, it was suggested that patients presenting with a single or few nonaggressive lesions and who respond well to conventional CD4? CTL treatment (localized radiotherapy and PUVA) should not be considered as having CD8TCL, and that two characteristic clinical features (disseminated ulcerated papules, plaques, nodules, and/or tumors without longstanding precursor lesions and an aggressive behavior that leads to rapid progression of the lesions over the skin surface and usually to extracutaneous sites) must be present to define this entity accurately [77] .
Primary cutaneous CD4? small/medium T-cell lymphoma Primary cutaneous CD4? small/medium T-cell lymphoma (CD4TCL) is associated with an excellent prognosis and presents characteristically with a solitary plaque or tumor that is generally localized on the face or the upper trunk and rarely presents with multiple papules, plaques, or tumors [80, 81] . Histologically, CD4TCL shows nodularto-diffuse infiltrates with a predominance of CD3?, CD4?, CD8-, CD30-small-to-medium-sized pleomorphic T cells and a small proportion (\30 %) of large CD4 pleomorphic T cells. In most cases, there is a considerable admixture with small reactive CD8? T cells and CD20? B cells [82] . Large atypical CD4? T cells express TFH-cell markers (PD-1, BCL-6, and CXCL-13) [83] . Although PD-1 is the most useful marker for the recognition of CD4TCL, pseudo T-cell lymphoma also expressed PD-1 [84] . Therefore, the distinction between these two groups is very difficult. T-cell monoclonality is not helpful for this discrimination, because not all CD4TCL cases are clonal and T-cell clonality has been demonstrated even in pseudo T-cell lymphomas with the advent of new and more sensitive techniques. The distinction from cutaneous B-cell lymphomas, such as cutaneous marginal zone B-cell lymphoma, is sometimes problematic because of the predominance of B-cell infiltrates.
Epstein-Barr virus (EBV)-associated T-or NK-cell lymphoproliferative disorders
EBV is an important factor that is associated with a higher incidence of T-or NK-cell lymphoma in East Asia compared with Europe and the USA. ENKL was the most common subtype in a Korean study, accounting for 89 of 107 EBV-positive T-or NK-type NHL cases (83 %), followed by aggressive NK-cell leukemia (8.4 %) [85] .
Extranodal NK/T-cell lymphoma ENKL, nasal type, is either of NK or T-cell lineage. The percentage of ENKL, nasal type, of T-cell origin, according to PCR-based research, ranges 0-38 % [86] . One phenotype study reported that ENKL, nasal type, was of NK origin (70 %), TCRcd? (5 %), TCRab? (3 %), TCRab/ cd? (1 %), and indeterminate (21 %) [87] . Deletion of chromosome 6q (6q21-6q25) is the most frequent genomic aberration, and the FOXO3 and PRDM1 tumor-suppressor genes have been identified in the 6q21-q25 region [88] . Studies have also demonstrated genetic aberrations related to important functions, including apoptosis (FAS), cell cycle (TP73, CDKN2A, CDKN2B, and CDKN1A), signaling pathways (KIT, CTNNB1, and JAK3), tumor-suppressor genes (TP53, PRDM1, AIM1, FOXO3, and HACE1), and oncogenes (RAS/KRAS/HRAS and MYC) [89] . Although the molecular profile of ENKL, nasal type, differs from that of other PTCLs, a subset of extranodal lymphomas derived from cd T cells has a molecular signature that is very similar to that of ENKL, nasal type [90] (Fig. 5 ).
EBV-positive T/NK-cell LPD of childhood EBV-positive T-cell LPD of childhood comprises a broad spectrum of EBV-associated LPDs with different clinical presentations, including systemic T-cell LPD of childhood, systemic chronic active EBV infection (CAEBV), hydrovacciniforme (HV)-type T-cell LPD, and mosquito-bite hypersensitivity. It is a very rare disease, and only sporadic cases or small series of this entity have been reported. Patients with CAEBV show a high viral load in the peripheral blood or in tissues, as well as chronic illness including fever, organomegaly, and skin lesions of unknown etiology. Clonal expansion and transformation of EBV-infected T and NK cells are the main pathogenic factors. The clinical course of this disease depends on the balance between EBV-related factors and host immune function, and can be smoldering, progressive, or aggressive. The EBV-infected T or NK cells in CAEBV frequently lack histological evidence of malignancy, and range from polyclonal, to oligoclonal, to monoclonal. Monoclonal cases of CAEBV are termed systemic T-cell LPD of childhood in the WHO 2008 classification [91] . Both HV and mosquito-bite allergy are cutaneous forms of CAEBV, but can progress to systemic involvement and a more fulminant disease. The spectrum of HV to HV-like T-cell lymphoma is somewhat of a continuum, but clinical, histological, and molecular features are all useful for its classification [30] .
